<DOC>
	<DOC>NCT02537210</DOC>
	<brief_summary>The purpose of this study is to determine whether aminosalicylic acid (ASA) can be safely withdrawn in patients with long-standing clinical inactive UC.</brief_summary>
	<brief_title>Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis</brief_title>
	<detailed_description>This is a randomized, double-blind, controlled trial in which patients with long-standing clinically inactive UC receiving ASA for maintenance of remission will be randomized to either continue 5-ASA or to receive an equivalent placebo for 12 months. The primary endpoint is clinical relapse at 12 months.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>have a confirmed diagnosis of UC according to established clinical, endoscopic and histologic criteria in longstanding clinical remission written informed consent allergic to mesalazine prior bowel surgery except appendectomy hepatic or renal dysfunction malignant disease within 5 years pregnancy or breast feeding or women of childbearing age without regular use of contraception on antitumor necrosis factor therapy terminal illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>